| P.O.Box 2345, Beijing 100023,China | World J Gastroenterol 2002 August 15;8(4):728-733 |
| Email: wcjd@public.bta.net.cn | WJG ISSN 1007-9327 CN 14-1219/ R |
| http:// www.wjgnet.com | Copyright © 2002 by The WJG Press |
Hepatoprotective role of ganoderma lucidum polysaccharide against BCG-induced immune liver injury in mice
Guo-Liang Zhang, Ye-Hong Wang, Wei Ni, Hui-Ling Teng, Zhi-Bin Lin
Guo-Liang Zhang, Ye-Hong Wang,
Wei Ni, Hui-Ling Teng, Zhi-Bin Lin, Department of Pharmacology, School of Basic
Medical Sciences, Beijing University, Beijing 100083, China
Supported by the
National Natural Science Foundation of China, No.39770861, No. 30171097; Beijing
University Center For Human Disease Genomics Research Foundation, No. 2000-A-1;
and JANSSEN Science Research Foundation
Presented at the third international symposium on hepatology, Hangzhou, China,
18-23 October, 2001
Correspondence to:
Dr. Guo-Liang Zhang, Department of Pharmacology, School of Basic Medical
Sciences, Beijing University, Beijing 100083, China. yuankui@public.bta.net.cn
Telephone: +86-10-62091421 Fax:
+86-10-62015681
Received 2002-03-12 Accepted 2002-04-23
Abstract
AIM: To examine the effect of ganoderma
lucidum polysaccharide (GLP) on the immune liver injury induced by BCG
infection, and investigate the relationship between degrees of hepatic damage
and NO production in mice.
METHODS: Immune hepatic injury was markedly induced by BCG-pretreatment
(125 mg·kg-1,
2-week, iv) or by BCG-pretreatment plus lipopolysaccharide (LPS, 125 mg·kg-1,
12-hour,iv) in mice in vivo.Hepatocellular damage induced by BCG-pretreated
plus inflammatory cytokines mixture (CM), which was included TNF-a, IL-1b, IFN-g
and LPS in culture medium in vitro. Administration of GLP was performed
by oral or incubating with culture medium at immune stimuli simultaneity. Liver
damage was determined by activity of alanine aminotransferase (ALT) in serum and
in hepatocytes cultured supernatant, by liver weight changes and
histopathological examination. NO production in the cultured supernatant was
determined by the Griess reaction. Moreover, inducible nitric oxide synthase (iNOS)
protein expression was also examinated by immunohistochemical method.
RESULTS: Immune hepatic injury was markedly induced by BCG or BCG plus
inflammatory cytokines in BALB/c mice in vivo and in vitro. Under
BCG-stimulated condition, augment of the liver weight and increase of the
serum/supernatant ALT level were observed, as well as granuloma forming and
inflammatory cells soakage were observed by microscopic analysis within liver
tissues. Moreover, NO production was also increased by BCG or/and CM stimuli in
the culture supernatant, and a lot of iNOS positive staining was observed in
BCG-prestimulated hepatic sections. Application of GLP significantly mitigated
hepatic tumefaction, decreased ALT enzyme release and NO production in
serum/supernatant, improved the pathological changes of chronic and acute
inflammation induced by BCG-stimuli in mice. Moreover, the immunohistochemical
result showed that GLP inhibited iNOS protein expression in BCG-immune hepatic
damage model.
CONCLUSION: The present study indicates that NO participates in immune
liver injury induced by Mycobacterium bovis BCG infection . The
mechanisms of protective roles by GLP for BCG-induced immune liver injury may be
due to influence NO production in mice.
Zhang GL, Wang YH, Ni W, Teng HL, Lin ZB. Hepatoprotective role of ganoderma
lucidum polysaccharide against BCG-induced immune liver injury in mice.World
J Gastroenterol 2002;8(4):728-733
INTRODUCTION
Ganoderma lucidum polysaccharide
(GLP) is an important pharmacological ingredient extracted from fruit bodies and
mycelium of mushroom Ganoderma Lucidum (Fr.) Karst. It has been
extensively documented that GLP can improve the damage induced by specific and
nonspecific immunity responses[1,2]. In our laboratory recently
studies, it was confirmed that GLP enhanced phagocytosis of intraperitoneal
macrophage, inhibited the growth of implanted Sarcoma 180 and HL-60 tumor cells in
vitro[3-5]. However, the regulating mechanism of GLP in the
immune response remain unknown. On the other hand, hepatitis is a prevalent
disease in the Chinese population. It has been recognized that the immune
factors, such as virus/parasite infection, autoimmune stimuli, etc., were the
dominant reasons of hepatic damage in hepatitis[6-10]. But the
commonly used model of liver injury induced by chemicals does not accurately
represent the clinical situation[11,12]. Therefore, It is required
that development of new therapy drugs depends primarily on the availability of
animal models relevant to human hepatitis or hepatocellular immune damage.
In the recently studies, Mycobacterium bovis bacillus
Calmette-Guerin (BCG) infection has been proven to induce immune hepatic injury
in rodent animal[13,14]. In this pathological model, the releases of
hepatic endogenous cytokines, such as TNF-a, IFN-g and IL-1b were observed in
vivo[15-17]. Moreover, in our laboratory previously experiment,
it has been observed that inflammatory cytokines including TNF-a and IL-1b
stimulated NO production in the primary cultured rat hepatocytes in vitro[18],
but the influence of GLP in this immune damage model and the exact function of
NO production in the presence of inflammatory stimuli have not been elucidated
yet. Therefore, the present study was performed to determine the effects of GLP
on the BCG-stimulated immune liver injury in vitro and in vivo,
and to investigate the possible mechanism of the influence induced by GLP in
this immune response.
MATERIALS AND METHODS
Reagents
Following reagents were purchased
from Sigma Chemical Co.: collagenase (Type IV, 340 kU·g-1),
bovine insulin, and lipopolysaccharide (LPS, E.coli.0111:B4). Other
materials were obtained from the following sources: kit for determining serum
and culture supernatant alanine transaminase (ALT) was from Beijing Institute of
Biological Products (Beijing); Mycobacterium tuberculosis Bacille
Calmette-Guerin (BCG) vaccine was from the National Vaccine and Serum Institute
(Beijing); human recombinant (rh) tumor necrosis factor-alpha (TNF-a),
interleukin-1 beta (IL-1b), interferon-gamma (IFN-g) were from Academy of
Military Medical Sciences (Beijing), and Dulbecco's modified
Eagle's medium (DMEM) from Gibco BRL; Ganoderma lucidum polysaccharide (GLP)
was isolated from mycelium of Ganoderma lucidum and provided by the
Department of Phytochemistry, College of Pharmacy, Beijing University[5].
For using immunohistochemistry, iNOS polyclonal antibody (rabbit
anti-mouse immunoglobulin) was purchased from Beijing Zhong-Shan Biotechnology
co., LTD.
Animals treatment and liver damage induction
Male BALB/c mice weighing 18-22g
(6-8 weeks old), were provided by Experimental Animal Center, Beijing
University. Immune hepatic injury was induced by intravenous injection of BCG
(125 mg·kg-1)
for two weeks, or induced by LPS (125 mg·kg-1)
for 12 hours at BCG-pretreated 14day later[13,19]. Control group mice
were treated by same volume of phosphate buffered saline (PBS). After animals
were BCG-pretreated 7 days, the different concentrations (25 mg·kg-1,
50 mg·kg-1,
100 mg·kg-1
and 200 mg·kg-1,
respectively) of GLP were intragastric administered once at everyday within
succedent one week. At immune stimulating 2 weeks later, mice were killed by
cervical dislocation,blood was collected and centrifuged at 3000 rpm for 5 min.
Serum was obtained at the supernatant for mensuration enzyme level. Liver
samples were removed rapidly for histopathological and immunohistochemical
examination.
Hepatocyte isolation and culture
Hepatocytes were harvested from
control mice or BCG-pretreated for 2 weeks mice using an in situ
collagenase perfusion technique[20]. After inhalation anesthesia, the
abdomen of the animals was opened and shaved,the portal vein was exposed and
cannulated. Then the liver was perfused at 37 ℃
in situ first with a calcium-free phosphate-buffered saline solution
(PBS) with 6~8 mL/min velocity of flow. This perfusion was continued for 5 min,
then it was switched to 0.5 g·L-1
collagenase and 10 g·L-1
bovine albumin in PBS buffer for 15 min. The liver was removed and the cells
were combed gently in tissue culture medium. Hepatocytes were pelleted, washed,
and separated from nonparenchymal cells by differential centrifugation at 50×g.
Viability of cells exceeded 85 % as determined by trypan blue exclusion.
Hapatocytes were plated onto 6-well plastic tissue-culture plates (1×109
cells·L-1
in each well). Medium in the control consisted of DMEM with L-arginine (0.5 mmol·L-1),
insulin (1 mmol·L-1),
Hepes (15mmol·L-1),
L-glutamine, penicillin, streptomycin, and 100 mL·L-1
low-endotoxin newborn calf serum. After overnight incubation, the medium was
changed with a cytokines mixture (CM) containing LPS (10 mg·L-1),
IL-1b (10 KU·L-1),
TNF-a (500 KU·L-1)
and IFN-g (100 KU·L-1).
Other experimental conditions included addition of GLP, at the different
concentrations (50 mg.L-1 or 200 mg.L-1), to the
CM. After primary cultures were maintained for 24 h at 37 ℃
in 50 ml·L-1
CO2, hepatocytes or cultured supernatants were collected for nitrite
and ALT activity assays[21].
Assay for hepatocellular enzyme release and NO production
As a marker of hepatocytes necrosis,
activity of alanine aminotransferase (ALT) was spectrophotometrically measured
using a determinating kit in serum and culture supernatants, at 520 nM in
the presence of a-ketoglutarate, aspartate, NADH and malate dehydrogenase, as
described[19]. The amount of NO production in the serum and the
culture supernatants were determined as its stable oxidative product, nitrite,
by an automated procedure based on the Griess reaction, as previously described[20].
Histopathological and immunohistochemical examination
Livers were removed, fixed overnight
in 10 % buffered formalin, and paraffin-embedded. Six-micrometer sections were
stained with hematoxylin-eosin for histological evaluation. Immunohistochemical
staining for iNOS protein expression was carried out using rabbit polyclonal
antibodies to iNOS on cryostat sections (five-micrometer). The sections were
incubated with peroxidase-labeled rabbit anti-mouse immunoglobulin for 1 hour.
After another wash in PBS, the sections were stained with AEC for several
minutes to develop the color and washed in water. Each experiment was repeated
two to three times with similar results. Three random sections of each liver
were examined[19].
Statistics analysis
Data were presented
with x±s,
Statistical analysis was performed using ANOVA. Differences were judged to be
statistically significant when the P value was less than 0.05.
RESULTS
Effect of Ganoderma lucidum
polysaccharide (GLP) on the liver weight and the activity of serum alanine
transaminase (ALT) in BCG-induced immune hepatic injury in mice in vivo
Compared with the control of group,
BCG-pretreatment markedly induced hepatic damage (Table 1). The augment of the
liver weight and the serum ALT level were observed after BCG-administrated 2
weeks in mice (P<0.01). Furthermore, application of inflammatory
lipopolysaccarides (LPS) for BCG-pretreated mice induced serum ALT activity
further higher than that BCG-treated alone in mice (P<0.05), but the
liver weights were not further increased than that BCG-stimulated only groups.
On the other hand, under the presence of BCG stimuli conditions, administration
of CLP decreased the liver weight within the range of 50 mg·kg-1
(P<0.05) to 200 mg·kg-1
(P<0.01), simultaneously, serum ALT release were significantly
decreased by GLP treatment in a dose-dependent manner within the similar range
of concentrations (P<0.05).
Table 1 Effect of Ganoderma lucidum polysaccharide (GLP) on the weight of
liver and the activity of serum alanine transaminase (ALT) in BCG-induced immune
hepatic injury in mice (x±s)
| Group | Liver weight (g) | ALT (U·L-1) |
| Control | 0.99±0.16 | 22.03±10.99 |
| BCG (125 mg·kg-1) | 1.79±0.24b | 245.18±41.03b |
| BCG (125 mg·kg-1) + LPS (125 mg·kg-1) | 1.84±0.14b | 285.88±23.81b,c |
| BCG (125 mg·kg-1) + GLP (25mg·kg-1) | 1.78±0.20b | 236.86±27.94b |
| BCG (125 mg·kg-1) + GLP (50mg·kg-1) | 1.57±0.18b, c | 189.81±43.99b,c |
| BCG (125 mg·kg-1) + GLP (100mg·kg-1) | 1.28±0.20b,d | 178.78±13.16b,d |
| BCG (125 mg·kg-1) + GLP (200mg·kg-1) | 1.41±0.43b,c | 208.18±27.93b,c |
aP<0.05,
bP<0.01 compared with control. cP< 0.05, dP<
0.01 compared with BCG-pretreated group. n=9 mice (liver weight groups)
or 10 mice (ALT groups).
Effect of Ganoderma lucidum polysaccharide (GLP) on the pathohistological
changes in BCG-stimulated hepatic tissues in mice in vivo
As shown in Figure 1, oppositing
with the results of control group, BCG-stimulated group were observed markedly
changes of liver histologic structure (Figure 1-B), for example, infiltration
within liver lobules by inflammatory cells, extensive hepatocytes hypertrophy,
nuclear narrow, and granulation and vacuolization of the hepatocyte cytoplasm
were observed in the liver section. Moreover, treatment with BCG plus LPS for
mice resulted in more severe histological changes including thrombosis in the
central hepatic vein and hemorrhage in the liver parenchyma(Figure1-C).
Granulomas formation, a marker of chronic hepatitis fibrosis'were
significantly increased by BCG-stimulated hepatic tissues (Tabel 2, P<0.01).
But in the presence of BCG condition, the result showh that LPS was not
triggered more the granuloma forming, on the contrary, triggered more fearful
hepatic tissues hemorrhage (Figure 1 B-C).
On the other hand, the results of histological
examination shown that GLP (100 mg·kg-1)
alleviated hepatic damage in BCG-induced acute inflammation, such as markedly
decrease of infiltration within liver lobules by inflammatory cells, nuclear
narrow,etc. in the observed liver section (Figure 1-D). Moreover, granulomas
formation were also decreased by GLP treatment at concentration range from 100
mg·kg-1
to 200 mg·kg-1,(P<0.01).
Figure 1 Histological changes of BCG-induced immune hepatic injury in the
presence or absence of Ganoderma lucidum polysaccharide (GLP) in mice.
Hematoxylin and eosin.Mice were treated with
(A) control,
(B) Bacille
Calmette-Guerin (BCG, 125 m·g·kg-1,
2 weeks) ,
(C) BCG plus lipopolysaccarides (LPS, 125 ug·kg-1,
12hr),
(D) BCG plus GLP (100 mg·kg-1),
as described in Materials and Methods. (Original magnification 200×)
Table 2 Effect of Ganoderma lucidum polysaccharide (GLP) on the granuloma formation (numbers/microscopic view) in BCG -pretrested mice hepatic histological slides. (x±s)
| Croup | Granulomas |
| Control | 0 |
| BCG (125 mg·kg-1) | 64.67±4.97b |
| BCG (125 mg·kg-1) + LPS (125 mg·kg-1) | 54.40±4.93b |
| BCG (125 mg·kg-1) + GLP (50mg·kg-1) | 60.00±4.24b |
| BCG (125 mg·kg-1) + GLP (100mg·kg-1) | 4.00±1.22b,d |
| BCG (125 mg·kg-1) + GLP (200mg·kg-1) | 36.80±5.81b,d |
aP<0.05, bP<0.01
compared with control. cP<0.05, dP<0.01
compared with BCG-pretreated group. n=5 microscopic views.
Effects of Ganoderma lucidum polysaccharide (GLP) on the ALT activity and NO
production induced by BCG in the presence or absence of cytokines mixture (CM)
in primary cultured mice hepatocytes in vitro
The result of this part of
experiment shown that inflammatory cytokines increased NO production and ALT
release into the supernatant in the primary cultured hepatocytes prestimulated
by BCG (P<0.01, Table 3). In the absence of cytokines condition,
addition of CLP only had not influence on the activity of ALT enzyme and NO
production in BCG-pretreated cultured supernatant (P>0.05). Whereas,
in the presence of inflammatory cytokines plus BCG prestimuli condition, ALT
activity and NO production were markedly inhibited by application of GLP (P<0.01).
CM (Cytokines mixture):IL-1b 10 KU·L-1,TNFa
500 KU·L-1,
and IFNg 100 KU·L-1
plus LPS 10 mg·L-1;
Cultured hepatocytes were harvested from control group, BCG-prestimulated group in
vivo, and BCG plus CM-stimulated group in vitro, respectively, in the
absence or presence of GLP for 24 h; Amount of nitrite and activity of ALT in
the supernatant were assayed 24 h after start of stimulation in vitro.
Table 3 Effects of Ganoderma lucidum polysaccharide (GLP) on the alanine
transaminase (ALT) activity and nitrite (NO2-) production induced by
BCG-prestimulating in the presence or absence of cytokines mixture (CM) in
primary cultured mice hepatocytes in vitro (x±s)
| Group | ALT (U·L-1) | NO2- (umol·L-1) |
| Control | 11.52±1.41b | 1.41±0.72a |
| BCG | 17.87±3.41 | 3.52±1.72 |
| BCG + GLP (50 mg·k-1) | 21.30±2.87 | 3.95±1.27 |
| BCG + GLP (200 mg·k-1) | 18.03±2.24 | 3.24±1.08 |
| BCG + Cytokines Mixture (CM) | 46.34±4.17b | 13.53±5.58b |
| BCG + CM + GLP (50 mg·k-1) | 23.98±6.33a, d | 4.11±2.26d |
| BCG + CM + GLP (200 mg·k-1) | 20.61±3.74d | 3.49±1.38d |
aP<0.05, bP<0.01
compared with BCG-pretreated group; cP<0.05, dP<0.01
compared with BCG+CM group. n=7 mice . (3 wells for each treatment in
each experiment).
Effect of Ganoderma lucidum polysaccharide (GLP) on the inducible nitirc oxide
synthase (iNOS) protein expression in BCG-stimulated mice hepatic tissues in
vivo
To confirm the possible mechanism
about hepatoprotective role of GLP against BCG-stimulated in mice, the
correlativity between iNOS expression and immune hepatic damage were
investigated. As shown in the results of immunohistochemistry, compared with
control group mice, there was a lot of iNOS positive brown stained agglomerate
observed in BCG-stimulated hepatic section (Figure 2 A-B). But consisted with
the results of granuloma forming , there were not more the iNOS expression
induced by LPS in the presence of BCG stimuli condition (Figure 2-C). On the
contrary, treatment of GLP significantly inhibited iNOS protein expression under
similary BCG-stimulated condidtion (Figure 2-D).
Figure 2 Immunohistochemical examination of inducible nitric oxide synthase
(iNOS) protein expression stimulated by BCG in the presence or absence of Ganoderma
lucidum polysaccharide (GLP) in mice. (Original magnification 200×). Mice
were treated with (A) control,
(B) Bacille Calmette-Guerin (BCG, 125 ug·kg-1,
2 weeks) ,
(C) BCG plus lipopolysaccarides (LPS, 125 mg·kg-1,
12hr),
(D) BCG plus GLP (100 mg·kg-1),
as described in Materials and Methods.
DISCUSSION
In the present experiment, the results
shown that the administration of GLP was effective against acute and chronic
hepatic inflammation induced by BCG-immunostimuli in mice. Administration of GLP
significantly decreased serum or supernatant ALT level in BCG-caused acute
inflammatory response in vivo and in vitro. Histological changes,
such as hemorrhage and necrosis in hepatic lobules, inflammatory infiltration of
lymphocytes and kupffer cells around the central vein, were simultaneously
improved by the treatment of GLP. These results were consistent with that GLP
showed anti-inflammatory and antioxidative activities in the previous other
laboratory observed results[22]. Moreover, pathohistological
examination also showed that GLP decreased the granuloma formation, which is
popularly considerd as the first step of fibrillar repair in the chronic
inflammatory process[23-26]. This result suggested that GLP may be
not only as an anti-inflammatory agent, but also may be used as an antifibrotic
therapy for hepatocirrhosis.
To investigate the possible mechanisms of the
hepatic protective effect of GLP in the immune-stimulated condition, we further
detected NO production in primary cultured hepatocytes and iNOS protein
expression in the BCG-stimulated hepatic tissues[27-30]. The results
shown that GLP alone had no effect on the production of NO in the cultured
hepatocytes. In the presence of BCG condition, cytokines mixture (CM) including
TNF-a , IFN-g , and LPS, significantly increased the NO production. When
combined with GLP, this effect had been remarkably reversed. At the same time
point, GLP also attenuated the increase of ALT activity in inflammatory
cytokines-stimulated hepatocytes in vitro. It has been recognized that NO
is produced by cNOS and/or iNOS in mice liver[31-37]. The results of
immunohistochemistry shown that GLP effect on NO production is mainly through
iNOS under immunological stimuli condition. The results of this study suggested
that although the exact mechanism of action of GLP on such macrophage/lymphocyte
properties of granulomas remain unknown, nevertheless, it might be related to NO
production induced by cytokines[38-42]. Therefore, inhibition of NO
production is partly the mechanisms of GLP protective effect on the
immunological injured liver.
In summary, the present study indicates that NO
participates in immune liver injury induced by Mycobacterium bovis BCG
infection. Furthermore, the mechanisms of protective roles by GLP for BCG-induced
immune liver injury in mice may be due to influence NO production. However,
further study is needed to understand the exact mechanisms of the
antihepatotoxic activity and the free radical scavenging activity of GLP. The
clinical applicability of GLP remains to be established.
REFERENCES
1
Bao XF,Liu CQ,Fang J,Li XY.Structural and immunological studies of a
major polysaccharide from spores of
Ganoderma lucidum (Fr.) Karst. Carbohydr
Res 2001;332:67-74
2
Cheung WM, Hui WS, Chu PW, Chiu SW, Ip NY. Ganoderma extract activates
MAP kinases and induces the neuronal
differentiation of rat pheochromocytoma PC12
cells. FEBS Lett 2000; 486:291-296
3 Ma L, Lin ZB. Effects of Ganoderma
polysaccharides on IL-2 production by mouse splenocytes in vitro.
J Beij Med Univ 1991;23:
412-417
4
Lei LS, Lin ZB. Effect of Ganoderma polysaccharides on T cell
subpopulations and production of interleukin 2 in mixed
lymphocyte response. Acta Pharmaceutica Sinica
1992; 27: 331-335
5 Zhang QH, Lin ZB. The antitumor activity of Ganoderma
lucidum (Curt.:Fr.) P. Karst. (Ling Zhi) (Aphyllophoromy cetideae)
polysaccharides is related to tumor nerosis
factor-a and interferon-g.Inter J Med Mushrooms 1999;1:207-215
6
Ouyang EC, Wu CH, Walton C, Promrat K, Wu GY. Transplantation of human
hepatocytes into tolerized genetically
immunocompetent rats.World J Gastroenterol 2001;7:324-330
7
Guo SP, Wang WL, Zhai YQ, Zhao YL. Expression of nuclear factor-kB in
hepatocellular carcinoma and its relation with the X
protein of hepatitis B virus. World J
Gastroenterol 2001;7:340-344
8
You J, Zhuang L, Tang BZ, Yang WB, Ding SY, Li W, Wu RX, Zhang HL, Zhang
YM, Yan SM, Zhang L. A randomized controlled
clinical trial on the treatkment of Thymosin-a 1
versus interferon-a in patients with hepatitis B.
World J Gastroenterol 2001;7:411-414
9
Li XW, Ding YQ, Cai JJ, Yang SQ, An LB, Qiao DF. Studies on mechanism of
Sialy Lewis-X antigen in liver metastases of human
colorectal carcinoma. World J Gastroenterol 2001;7:
425-430
10
Liu BH, Chen HS, Zhou JH, Xiao N. Effects of endotoxin on endothelin
receptor in hepatic and intestinal tissues after
endotoxemia in rats. World J Gastroenterol
2000;6:298-300
11
Cheng JL, Tong WB, Liu BL, Zhang Y, Yan Z, Feng BF. Hepatitis C virus in
human B lymphocytes transformed by Epstein-Barr
virus in vitro by in situ reverse
transcriptase-polymerase chain reaction. World J Gastroenterol 2001;7:370-375
12
Zhuang L, You J, Tang BZ, Ding SY, Yan KH, Peng D, Zhang YM , Zhang L.
Preliminary results of Thymosin-a 1 versus
interferon-a treatment in patients with Hbe-AG
negative and serum HBV DNA positive chronic hepatitis B.
World J Gastroenterl 2001;7:407-410
13
Carpenter E, Fray L, Gormley E. Antigen-specific lymphocytes enhance
nitric oxide production in Mycobacterium bovis
BCG-infected bovine macrophages. Immunol
Cell Biol 1998; 76:363-368
14
Wang GS, Liu GT. Role of nitric oxide in immunological liver damage in
mice. Biochem Pharmacol 1995; 49:1277-1281
15
Bai XY, Jia XH, Cheng LZ, Gu YD. Influence of IFN-2b and BCG on the
release of TNF and IL-1 by Kupffer cells in rats with
hepatoma.World J Gastroenterol 2001;7:419-421
16
Erb KJ, Kirman J, Delahunt B, Chen WX, Gros GL. IL-4, IL-5 and IL-10 are
not required for the control of M. Bovis-BCG infection
in mice. Immunol Cell Biol 1998; 76:
41-46
17
Ugaz EMA, Pinheiro SR, Guerra JL, Palermo-Neto J. Effects of prenetal
diazepam treatnent on Mycobacterium bovis-induced
infection in hamsters. Immunopharmacology
1999; 41: 209-217
18 Zhang GL, Lin ZB. Effects of cytokines on the endotoxin
stimulated nitric oxide production in the primary cultured rat
hepatocytes. Beijing Yike Daxue Xuebao
1998;30:180-182
19 Zhang GL, Lin ZB, Zhang B. Effects of selective induceble nitric
oxide synthase inhibitor on immunological hepatic injury in rat.
Zhanghua Yixue Zazhi 1998; 78:
540-543
20
Zhang GL, Lin ZB. Dinoprostone potentiates cytokines and
lipopolysaccarides to induce nitric oxide production in cultured rat
hepatocytes. Acta Pharmacol Sinica 1999; 20:
262-266
21
Zhang GL, Wang YH, Teng HL, Lin ZB. Effects of aminoguanidine on the
nitric oxide production induced by inflammatory
cytokines and endotoxin in cultured rat
hepatocytes. World J Gastroenterol 2001;7: 331-334
22
Lee JM, Kwon H, Jeong H, Lee JW, Lee SY, Baek SJ, Surh YJ. Inhibition of
lipid peroxidation and oxidative DNA damage by
Ganoderma lucidum. Phytother Res 2001;15:245-249
23
Nie QH, Cheng YQ, Xie YM, Cao YZ. Inhibiting effect of antisense
oligonucleotides phosphorthioate on gene expression of TIMP-
1 in rat liver fibrosis. World J Gastroenterol
2001;7: 363-369
24 Huang YQ, Xiao SD, Mo JZ, Zhang DZ. Effects of nitric oxide
synthesis inhibitor in long term treatment on hyperdynamic
circulatory state in cirrhotic rats. World J
Gastroenterol 2000;6 (Suppl 3):31
25 Feng ZJ, Feng LY, Sun ZM, Song M, Yao XX. Expression of nitric
oxide synthase protein and gene in the splanchnic organs of
liver cirrhosis and portal hypertensive rats. World
J Gastroenterol 2000;6 (Suppl 3):33
26
Vernia S, Beaune P, Coloma J, Lopez-Garcia PM. Differential sensitivity
of rat hepatocyte CYP isoforms to self- generated
nitric oxide. FEBS Lett 2001;488:
59-63
27
Wang JH, Redmond HP, Wu QD, Bouchier-Hayes D. Nitric oxide mediates
hepatocyte injury.
Am J Physiol 1998; 275:
G1117-G1126
28
Alexander B. The role of nitric oxide in hepatic metabolism. Nutrition
1998; 14: 376-390
29
Kaibori M, Sakitani K, Oda M, Kamiyama Y, Masu Y, Nishizawa M, Ito S,
Okumura T. Immunosuppressant FK506 inhibits
inducible nitric oxide synthase gene expression
at a step of NF-kB activation in rat hepatocytes. J Hepatol 1999;30:
1138-1145
30
McCafferty DM, Mudgett JS,Swain MG,Kubes P.Inducible nitric oxide
synthase plays a critical role in resolving intestinal
inflammation. Gastroenterology 1997;112:1022-1027
31
Moriyama A, Tabaru A, Unoki H, Abe S,Masumoto A, Otsuki M. Plasma
nitrite/nitrate concentrations as a tumor marker for
hepatocellular carcinoma. Clinica Chimica Acta
2000; 296: 181-191
32
Hara H, Mitani N, Adachi T. Inhibitory effect of nitric oxide on the
induction of cytochrome P450 3A4 mRNA by 1,25
dihydroxyvitamin D3 in Caco-2 cells. Free Rad
Res 2000; 33: 279-285
33
Yu J, Guo F, Ebert MPA, Malfertheiner P. Expression of inducible nitric
oxide synthase in human gastric cancer.
World J Gastroenterol 1999;5:430-431
34
Ji XL, Shen MS, Yin T. Liver inflammatory pseudotumor or parasitic
granuloma? World J Gastroenterol 2000;6:458-460
35
Heneka MT, Loschmann PA, Gleichmann M, Weller M, Schulz JB, Wullner U,
Klockgether T. Induction of nitric oxide synthase
and nitric oxide-mediated apoptosis in neuronal
PC12 cells after stimulation with tumor necrosis factor-a / lipopolysaccharide.
J Neurochem 1998; 71: 88-94
36
Liu SH, Tzeng HP, Kuo ML, Lin-Shiau SY. Inhibition of inducible nitric
oxide synthase by b-lapachone in rat alveolar macrophages
and aorta. Br J Pharmacol 1999;126:
746-750
37
Vos TA, Gouw AS, Klok PA, Havinga R, Goor H, Huitema S, Roelofsen H,
Kuipers F, Jansen P, Moshage H. Differential effects
of nitric oxide synthase inhibitors on endotoxin-induced
liver damage in rats. Gastroenterology 1997; 113: 1323-1333
38
Tzeng E, Billiar TR, Williams DL, Li J, Lizonova A, Kovesdi I, Kim YM, Pa
P. Adenovirus-mediated inducible nitric oxide
synthase gene transfer inhibits hepatocyte
apoptosis. Surgery 1998;124: 278-283
39
Nomura T, Ohtsuki M, Matsui S, Sumi-Ichinose C, Nomura H, Hagino Y.
Nitric oxide donor NOR3 inhibits ketogenesis from
oleate in isolated rat hepatocytes by a cyclic
GMP-independent mechanism. Pharmacol Tox 1998;82: 40-46
40
Imagawa J, Yellon DM, Baxter GF. Pharmacological evidence that inducible
nitric oxide synthase is a mediator of delayed
preconditioning. Br J Pharmacol 1999; 126:
701-708
41
Tunctan B, Uludag O, Altug S, Abacloglu N. Effects of nitric oxide
synthase inhibition in lipopolysaccharide-induced sepsis in
mice. Pharmacol Res 1998;38:
405-411
42
Ohmori H, Egusa H, Ueura N, Matsumoto Y, Kanayama N, Hikida M. Selective
augmenting effects of nitric oxide on
antigen-specific IgE response in mice. Immunopharmacology
2000;46: 55-63
Edited by Pang LH